Literature DB >> 15864692

Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes.

Haruhiko Kondo1, Takehiro Okumura, Yasuhisa Ohde, Kazuo Nakagawa.   

Abstract

Surgical resection is an important modality in the treatment of pulmonary metastases from various solid tumors. The criteria for pulmonary metastasectomy are as follows: (1) the patient must be a good risk for surgical intervention; (2) the primary malignancy is controlled; (3) there is no other, extrapulmonary, metastasis; and (4) the pulmonary lesions are thought to be completely resectable. The appropriate selection of candidates according to these criteria leads to an overall 5-year survival after pulmonary metastasectomy of about 30%-40%. However, most of the reported results are retrospective analyses, and the significance of pulmonary metastasectomy seems to vary according to the primary malignancy. To clarify the significance of surgical treatment for pulmonary metastases, we need further analysis of various prognostic factors, with special reference to each primary malignancy, as well as a multiinstitutional study, and randomized prospective studies, if possible.

Entities:  

Mesh:

Year:  2005        PMID: 15864692     DOI: 10.1007/s10147-004-0472-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  22 in total

Review 1.  Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection.

Authors:  Masahiko Higashiyama; Toshiteru Tokunaga; Tomoyuki Nakagiri; Daisuke Ishida; Hidenori Kuno; Jiro Okami
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-04-03

2.  Stereotactic body radiation therapy versus metastasectomy for oligometastases.

Authors:  Haoming Qiu; Alan W Katz; Michael T Milano
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 3.  Past, present, and future perspectives of pulmonary metastasectomy for patients with advanced colorectal cancer.

Authors:  Tomohiro Murakawa
Journal:  Surg Today       Date:  2020-08-28       Impact factor: 2.549

4.  Editorial on "Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size?"

Authors:  Stefano M M Basso; Sandro C Sulfaro; Paolo Ubiali
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 5.  Preoperative Evaluation and Indications for Pulmonary Metastasectomy.

Authors:  Loretta Erhunmwunsee; Betty C Tong
Journal:  Thorac Surg Clin       Date:  2016-02       Impact factor: 1.750

Review 6.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

7.  The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas.

Authors:  Hiromasa Yamamoto; Kei Namba; Haruchika Yamamoto; Tomohiro Toji; Junichi Soh; Kazuhiko Shien; Ken Suzawa; Takeshi Kurosaki; Shinji Otani; Mikio Okazaki; Seiichiro Sugimoto; Masaomi Yamane; Katsuhito Takahashi; Toshiyuki Kunisada; Takahiro Oto; Shinichi Toyooka
Journal:  Surg Today       Date:  2020-08-03       Impact factor: 2.549

8.  Long-term survival in a patient with repeated resections for lung metastasis after hepatectomy for ruptured hepatocellular carcinoma: a case report.

Authors:  Kai-Lun Shih; Yang-Yuan Chen; Tsung-Han Teng; Maw-Soan Soon
Journal:  J Med Case Rep       Date:  2008-06-30

9.  Radiofrequency ablation of thoracic tumours: lessons learned with ablation of 100 lesions.

Authors:  Irene Garetto; Marco Busso; Diego Sardo; Claudia Filippini; Federica Solitro; Maria Luisa Grognardi; Andrea Veltri
Journal:  Radiol Med       Date:  2013-11-15       Impact factor: 3.469

10.  Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative.

Authors:  Marilee Carballo; Mary S Maish; Dawn E Jaroszewski; Amy Yetasook; Karl Bauer; Robert B Cameron; E Carmack Holmes
Journal:  Surg Endosc       Date:  2008-12-31       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.